This study looks at the long-term safety and effectiveness of a drug called amlitelimab for people with a skin condition called atopic dermatitis (AD). AD is a condition that makes the skin red, itchy, and sometimes scaly. This study is for people who were part of earlier trials with amlitelimab. Participants will visit the study site every 4 weeks. Some participants will stop taking the drug for a while to see how their skin responds. If their symptoms come back, they will start taking the drug again. Others will continue taking the drug without stopping. The drug can be given at home by the participant, a caregiver, or a healthcare professional, depending on what the doctor thinks is best. If someone stops taking amlitelimab for good, they will be checked for at least 140 days to make sure they're okay.

• The study involves regular visits every 4 weeks.
• Participants may take the drug at home.
• Safety checks continue for 140 days after stopping the drug.